|1.||Ohta, T: 2 articles (09/2005 - 06/2001)|
|2.||Furukawa, N: 1 article (09/2005)|
|3.||Sasase, T: 1 article (09/2005)|
|4.||Matsushita, M: 1 article (09/2005)|
|5.||Matsui, K: 1 article (09/2005)|
|6.||Yonemori, F: 1 article (09/2005)|
|7.||Miyajima, K: 1 article (09/2005)|
|8.||Ohta, Takeshi: 1 article (08/2003)|
|9.||Furukawa, Noboru: 1 article (08/2003)|
|10.||Komuro, Goro: 1 article (08/2003)|
09/01/2005 - "In examination of other diabetic complications, JTT-608 ameliorated the reduced motor nerve conduction velocities observed in diabetic rats and inhibited the incidence of cataracts with diabetes. "
09/01/2005 - "We conclude that a newly developed antidiabetic agent, JTT-608, improves the pancreatic function and prevents the development of diabetic complications by inhibition of daily postprandial hyperglycaemia and could be useful for the treatment of diabetic subjects with impaired insulin secretion."
09/01/2005 - "Haemoglobin A1C (HbA1C) and fasting blood glucose levels were measured at 4-week intervals, and effects of JTT-608 on pancreatic function and diabetic complications were examined after dosing period. "
|2.||Type 2 Diabetes Mellitus (MODY)
06/01/2001 - "The present findings indicate that JTT-608 is a more useful new class of therapeutic drug for patients with non-insulin-dependent diabetes mellitus, compared with sulfonylurea derivatives."
04/01/1999 - "1. We investigated the pharmacological effects of a new antidiabetic agent, JTT-608, in comparison with the sulphonylurea tolbutamide, in Goto-Kakizaki (GK) rats, a genetic model of non-obese insulin-dependent diabetes mellitus (NIDDM). "
04/23/1999 - "In isolated, perfused pancreas of neonatally streptozotocin-induced non-insulin-dependent diabetes mellitus rats (nSTZ rats), JTT-608 (200 microM) normalized the first phase and doubled the second phase of insulin secretion. "
|4.||Hypoglycemia (Reactive Hypoglycemia)
|5.||Diabetic Neuropathies (Diabetic Neuropathy)
|2.||Blood Glucose (Blood Sugar)